Dynamic path analysis – a useful tool to investigate mediation processes in clinical survival trials
暂无分享,去创建一个
Ørnulf Borgan | Odd O Aalen | Susanne Strohmaier | Kjetil Røysland | Rune Hoff | Terje R Pedersen | O. Aalen | Ø. Borgan | K. Røysland | T. Pedersen | S. Strohmaier | R. Hoff | Ørnulf Borgan
[1] O. Aalen. A linear regression model for the analysis of life times. , 1989, Statistics in medicine.
[2] P. Andersen,et al. Dynamic path analysis in life-course epidemiology. , 2011, American journal of epidemiology.
[3] Po-Ling Loh,et al. High-dimensional learning of linear causal networks via inverse covariance estimation , 2013, J. Mach. Learn. Res..
[4] S. Cole,et al. Fallibility in estimating direct effects. , 2002, International journal of epidemiology.
[5] O. Faergeman,et al. Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL study , 2009, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.
[6] B. Ledergerber,et al. Analyzing direct and indirect effects of treatment using dynamic path analysis applied to data from the Swiss HIV Cohort Study , 2011, Statistics in medicine.
[7] Niels Keiding,et al. Statistical Models Based on Counting Processes , 1993 .
[8] P. Holland. Causal Inference, Path Analysis and Recursive Structural Equations Models. Program Statistics Research, Technical Report No. 88-81. , 1988 .
[9] O. Aalen,et al. Survival and Event History Analysis: A Process Point of View , 2008 .
[10] O. Faergeman,et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. , 2005, JAMA.
[11] Odd O Aalen,et al. Dynamic Analysis of Recurrent Event Data Using the Additive Hazard Model , 2006, Biometrical journal. Biometrische Zeitschrift.
[12] J. Robins,et al. Identifiability and Exchangeability for Direct and Indirect Effects , 1992, Epidemiology.
[13] R. Emsley,et al. interventions Mediation and moderation of treatment effects in randomised controlled trials of complex , 2010 .
[14] Stijn Vansteelandt,et al. Estimation of direct effects for survival data by using the Aalen additive hazards model , 2011 .
[15] O. Aalen,et al. Dynamic path analysis—a new approach to analyzing time-dependent covariates , 2006, Lifetime data analysis.
[16] Tyler J VanderWeele,et al. Alternative Assumptions for the Identification of Direct and Indirect Effects , 2011, Epidemiology.
[17] J. Pearl. Causality: Models, Reasoning and Inference , 2000 .
[18] Stijn Vansteelandt,et al. On collapsibility and confounding bias in Cox and Aalen regression models , 2013, Lifetime data analysis.
[19] J. Pearl. The Causal Mediation Formula—A Guide to the Assessment of Pathways and Mechanisms , 2012, Prevention Science.
[20] D. A. Kenny,et al. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. , 1986, Journal of personality and social psychology.
[21] V. Ramjee,et al. Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification: do the math. , 2011, Journal of the American College of Cardiology.
[22] B. Graubard,et al. Statistical validation of intermediate endpoints for chronic diseases. , 1992, Statistics in medicine.
[23] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[24] Tyler J VanderWeele,et al. Causal Mediation Analysis With Survival Data , 2011, Epidemiology.
[25] P. Renshaw,et al. [Detection, evaluation, and treatment of high blood cholesterol in adults]. , 2001, Revista panamericana de salud publica = Pan American journal of public health.
[26] Richard Emsley,et al. Ian R White interventions Mediation and moderation of treatment effects in randomised controlled trials of complex , 2010 .
[27] O. D. Duncan. Path Analysis: Sociological Examples , 1966, American Journal of Sociology.
[28] D. Rubin. Estimating causal effects of treatments in randomized and nonrandomized studies. , 1974 .
[29] A. Sniderman,et al. Reliability of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B measurement. , 2011, Journal of clinical lipidology.
[30] O. Aalen,et al. Can we believe the DAGs? A comment on the relationship between causal DAGs and mechanisms , 2014, Statistical methods in medical research.
[31] Odd Aalen,et al. A Model for Nonparametric Regression Analysis of Counting Processes , 1980 .
[32] Judea Pearl,et al. Direct and Indirect Effects , 2001, UAI.
[33] A. Goldberger. STRUCTURAL EQUATION METHODS IN THE SOCIAL SCIENCES , 1972 .
[34] T. Martinussen,et al. Dynamic path analysis for event time data: large sample properties and inference , 2010, Lifetime data analysis.
[35] A. Keech,et al. Relationship Between Lipid Levels and Clinical Outcomes in the Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) Trial: To What Extent Is the Reduction in Coronary Events With Pravastatin Explained by On-Study Lipid Levels? , 2002, Circulation.
[36] O. Faergeman,et al. Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study. , 2004, The American journal of cardiology.
[37] Els Goetghebeur,et al. Estimation of controlled direct effects , 2008 .
[38] Richard F MacLehose,et al. A further critique of the analytic strategy of adjusting for covariates to identify biologic mediation. , 2004, Epidemiologic perspectives & innovations : EP+I.
[39] Theis Lange,et al. Direct and Indirect Effects in a Survival Context , 2011, Epidemiology.
[40] S. Wright. The Method of Path Coefficients , 1934 .
[41] P. Toth. Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins: A Meta-analysis , 2012 .